Delpor is a clinical stage life sciences company that utilizes innovative drug-delivery technologies in order to develop once-yearly therapies for chronic conditions. The Company’s lead product is a 6-12-month formulation of Risperidone (drug/device combination product) for the treatment of schizophrenia. Delpor is also pursuing 6-12 month formulations of other drugs targeting CNS conditions including Neuromuscular Diseases, Neurodegenerative Diseases, Addiction, and other disorders.